Area of research
Nephrology · Critical Care and Intensive Care Medicine
Research interest
Research interests include Medicine, Internal medicine, Renal function, Kidney disease, Lupus nephritis, and Urinary system.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent <i>Clostridioides difficile</i> Infection
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in Elders
Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus
Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine–Defined Acute Kidney Injury in Infants After Cardiac Surgery
Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study
Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
Urinary Uromodulin and Risk of Urinary Tract Infections: The Cardiovascular Health Study
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Predicting decline of kidney function in lupus nephritis using urine biomarkers
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity
Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults
Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults
Association of Urinary Injury Biomarkers with Mortality and Cardiovascular Events
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Tolerance of the Human Kidney to Isolated Controlled Ischemia
Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis